[{"id":"4082ae60-844c-4356-b0ed-58114e9bb5d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877083","created_at":"2021-01-18T08:26:53.340Z","updated_at":"2024-07-02T16:36:57.011Z","phase":"Phase 2","brief_title":"Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung","source_id_and_acronym":"NCT01877083","lead_sponsor":"Eisai Inc.","biomarkers":" KRAS • ALK • RET • KIF5B • CCDC6","pipe":" | ","alterations":" RET positive","tags":["KRAS • ALK • RET • KIF5B • CCDC6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 04/05/2013","start_date":" 04/05/2013","primary_txt":" Primary completion: 02/03/2016","primary_completion_date":" 02/03/2016","study_txt":" Completion: 11/02/2017","study_completion_date":" 11/02/2017","last_update_posted":"2019-08-13"}]